To the editor [2]

New England Journal of Medicine

Volumn 354, Issue 17, 2006, Pages 1846-1847

  Meltzer, Herbert Y ^a   Yaǧcioǧlu, Elif Anil ^b   Akdede, Berna Binnur Kivircik ^c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HACETTEPE UNIVERSITY   (Turkey)

^c DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE;

CLINICAL TRIAL; HUMAN; LETTER; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 33646100741     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc060588     Document Type: Letter

References (1)

1. Anil Yaǧcioǧlu AE, Kivircik Akdede BB, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005;66:63-72.